{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "ABCB1",
      "COVID-19",
      "CYP2D6",
      "CYP3A4",
      "NR1I2",
      "pharmacogenetics"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33807592",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "19"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "03",
        "Day": "05"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "413",
      "10.3390/v13030413"
    ],
    "Journal": {
      "ISSN": "1999-4915",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "3",
        "PubDate": {
          "Year": "2021",
          "Month": "Mar",
          "Day": "05"
        }
      },
      "Title": "Viruses",
      "ISOAbbreviation": "Viruses"
    },
    "ArticleTitle": "Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.",
    "Abstract": {
      "AbstractText": [
        "The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients' outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatment. We aimed to describe the pharmacogenetic variants reported for drugs used for COVID-19 treatment (remdesivir, oseltamivir, lopinavir, ritonavir, azithromycin, chloroquine, hydroxychloroquine, ivermectin, and dexamethasone). In addition, other factors relevant to the design of pharmacogenetic studies were mentioned. Variants in <i>CYP3A4</i>, <i>CYP3A5</i>, <i>CYP2C8</i>, <i>CY2D6</i>, <i>ABCB1</i>, <i>ABCC2</i>, and <i>SLCO1B1</i>, among other variants, could be included in pharmacogenetic studies of COVID-19 treatment. Besides, nongenetic factors such as drug-drug interactions and inflammation should be considered in the search for personalized therapy of COVID-19."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-2132-1076"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Mexico City 14080, Mexico."
          }
        ],
        "LastName": "Fricke-Galindo",
        "ForeName": "Ingrid",
        "Initials": "I"
      },
      {
        "Identifier": [
          "0000-0001-6877-8124"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Mexico City 14080, Mexico."
          }
        ],
        "LastName": "Falf\u00e1n-Valencia",
        "ForeName": "Ramc\u00e9s",
        "Initials": "R"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Viruses",
    "NlmUniqueID": "101509722",
    "ISSNLinking": "1999-4915"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "ABCC2 protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Multidrug Resistance-Associated Protein 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "genetics",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Multidrug Resistance-Associated Protein 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pharmacogenetics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pharmacogenomic Variants"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}